Shanghai Mayor Gong Zheng meets with Chairman and CEO of Boston Scientific Corporation, Michael Mahoney.

Shanghai Mayor Gong Zheng met with Martin M. Harris, Chairman and CEO of Boston Scientific Corporation today. Gong Zheng said that currently, we are focusing on the construction of the "Five Centers", accelerating the development of Shanghai into a socialist modern international metropolis with world influence. Biomedicine is one of Shanghai's key development industries. Shanghai has significant innovative resources in the field of biomedicine. We will continue to enhance the technological innovation capability of the biomedicine industry, deepen the international development of the industry, and accelerate the creation of a globally influential biomedicine industry innovation hub. We hope that Boston Scientific will continue to optimize its functional layout in Shanghai, actively support the development of Shanghai's biomedicine industry, deeply participate in the construction of Shanghai International Science and Technology Innovation Center, and achieve greater success in Shanghai. At the same time, we welcome the company to continue participating in the China International Import Expo. Shanghai will continue to build a first-class market-oriented, rule-of-law and internationalized business environment, providing better conditions for all types of business entities to develop in Shanghai. Martin M. Harris said that I have visited China more than 30 times and the rapid development of China and Shanghai is amazing. The Chinese market is of great strategic significance to Boston Scientific, and the company's business in China has achieved rapid development and expansion in recent years. Shanghai's innovative research and development capabilities continue to improve and the business environment is constantly optimized, providing strong support for the company's development. Facing the complex and ever-changing international situation, we are always confident in China and will continue to increase investment in China and Shanghai, expand our business scope, increase research and development investment, and better meet the needs of Chinese patients.